Melior Discovery, Inc. is a leader in the transformation of pharmaceutical drug repositioning with its unique theraTRACE platform of multiplexed in vivo models.
Now, it has signed a research agreement with Pfizer (NYSE: PFE) enabling the company to utilize its in vivo theraTRACE indications discovery platform for the evaluation of the activity of selected Pfizer compounds.
According to Andrew Reaume, PhD, President and CEO of Melior:
"Our agreement represents a significant opportunity for Melior to deliver value to Pfizer through the application of our unique and innovative in vivo testing platform. We look forward to a productive collaboration."Source: Melior Discovery, Inc. (a pdf file)
Comment Preview